Volume 97, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Preventive chemotherapy with praziquantel for schistosomiasis morbidity control is commonly done by mass drug administration (MDA). MDA regimen is usually based on prevalence in a given area, and effectiveness is evaluated by decreases in prevalence and/or intensity of infection after several years of implementation. Multiple studies and programs now find that even within well-implemented, multiyear, annual MDA programs there often remain locations that do not decline in prevalence and/or intensity to expected levels. We term such locations “persistent hotspots.” To study and address persistent hotspots, investigators and neglected tropical disease (NTD) program managers need to define them based on changes in prevalence and/or intensity. But how should the data be analyzed to define a persistent hotspot? We have analyzed a dataset from an operational research study in western Tanzania after three annual MDAs using four different approaches to define persistent hotspots. The four approaches are 1) absolute percent change in prevalence; 2) percent change in prevalence; 3) change in World Health Organization guideline categories; 4) change (absolute or percent) in both prevalence and intensity. We compare and contrast the outcomes of these analyses. Our intent is to show how the same dataset yields different numbers of persistent hotspots depending on the approach used to define them. We suggest that investigators and NTD program managers use the approach most suited for their study or program, but whichever approach is used, it should be clearly stated so that comparisons can be made within and between studies and programs.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. WHO, 2001. Resolution WHA54.19. Schistosomiasis and Soil-Transmitted Helminth Infections. Fifty-Fourth World Health Assembly. Geneva, Switzerland: WHO.
  2. Fenwick A et al., 2009. The schistosomiasis control initiative (SCI): rationale, development and implementation from 2002–2008. Parasitology 136: 17191730.
    [Google Scholar]
  3. Garba A, Toure S, Dembele R, Boisier P, Tohon Z, Bosque-Oliva E, Koukounari A, Fenwick A, 2009. Present and future schistosomiasis control activities with support from the schistosomiasis control initiative in west Africa. Parasitology 136: 17311737.
    [Google Scholar]
  4. Ndayishimiye O, Ortu G, Soares Magalhaes RJ, Clements A, Willems J, Whitton J, Lancaster W, Hopkins A, Fenwick A, 2014. Control of neglected tropical diseases in Burundi: partnerships, achievements, challenges, and lessons learned after four years of programme implementation. PLoS Negl Trop Dis 8: e2684.
    [Google Scholar]
  5. WHO, 2012. Resolution WHA65.21. Elimination of Schistosomiasis. Sixty-Fifth World Health Assembly. Geneva, Switzerland: WHO.
  6. WHO, 2013. Resolution WHA66.12. Neglected Tropical Diseases. Sixty-Sixth World Health Assembly. Geneva, Switzerland: WHO.
  7. Andrade G, Bertsch DJ, Gazzinelli A, King CH, 2017. Decline in infection-related morbidities following drug-mediated reductions in the intensity of Schistosoma infection: a systematic review and meta-analysis. PLoS Negl Trop Dis 11: e0005372.
    [Google Scholar]
  8. Kabatereine NB, Brooker S, Koukounari A, Kazibwe F, Tukahebwa EM, Fleming FM, Zhang Y, Webster JP, Stothard JR, Fenwick A, 2007. Impact of a national helminth control programme on infection and morbidity in Ugandan schoolchildren. Bull World Health Organ 85: 9199.
    [Google Scholar]
  9. Pennance T, Person B, Muhsin MA, Khamis AN, Muhsin J, Khamis IS, Mohammed KA, Kabole F, Rollinson D, Knopp S, 2016. Urogenital schistosomiasis transmission on Unguja Island, Zanzibar: characterisation of persistent hot-spots. Parasit Vectors 9: 646.
    [Google Scholar]
  10. Ezeamama AE et al., 2016. Gaining and sustaining schistosomiasis control: study protocol and baseline data prior to different treatment strategies in five African countries. BMC Infect Dis 16: 229.
    [Google Scholar]
  11. WHO, 2006. Preventive Chemotherapy in Human Helminthiasis: Coordinated Use of Anthelminthic Drugs in Control Interventions: A Manual For Health Professionals and Programme Managers. Geneva, Switzerland: World Health Organization.
  12. Landis JR, Koch GG, 1977. The measurement of observer agreement for categorical data. Biometrics 33: 159174.
    [Google Scholar]
  13. Richards FO Jr, Eigege A, Miri ES, Jinadu MY, Hopkins DR, 2006. Integration of mass drug administration programmes in Nigeria: the challenge of schistosomiasis. Bull World Health Organ 84: 673676.
    [Google Scholar]
  14. Colley DG, Bustinduy AL, Secor WE, King CH, 2014. Human schistosomiasis. Lancet 383: 22532264.
    [Google Scholar]
  15. Chu BK et al., 2013. Transmission assessment surveys (TAS) to define endpoints for lymphatic filariasis mass drug administration: a multicenter evaluation. PLoS Negl Trop Dis 7: e2584.
    [Google Scholar]

Data & Media loading...

Supplemental Table

  • Received : 09 May 2017
  • Accepted : 11 Jul 2017
  • Published online : 25 Sep 2017
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error